Treatment of renal cell carcinoma: Current status and future directions

被引：685

作者：

Barata, Pedro C. ^{[1
]}

Rini, Brian I. ^{[2
,3
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[2] Cleveland Clin, Lerner Coll Med, Med, Cleveland, OH 44106 USA

[3] Cleveland Clin, Taussig Canc Inst, Genitourinary Program, Glickman Urol & Kidney Inst,Dept Hematol & Oncol, Cleveland, OH 44106 USA

来源：

CA-A CANCER JOURNAL FOR CLINICIANS | 2017年 / 67卷 / 06期

关键词：

clinical trials; immunotherapy; programmed death 1 (PD-1); renal cell carcinoma; targeted agents; vascular endothelial growth factor (VEGF); ENDOTHELIAL GROWTH-FACTOR; DOSE RECOMBINANT INTERLEUKIN-2; INTEGRATED STAGING SYSTEM; INITIAL TARGETED THERAPY; PHASE-III TRIAL; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; OPEN-LABEL; DOUBLE-BLIND; HIGH-RISK;

D O I：

10.3322/caac.21411

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agentsincluding molecules against vascular endothelial growth factor, platelet-derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin and the MET and AXL tyrosine-protein kinase receptors; and an immune-checkpoint inhibitorhave been approved based on significant activity in patients with advanced RCC. Despite these advances, important questions remain regarding biomarkers of efficacy, patient selection, and the optimal combination and sequencing of agents. The purpose of this review is to summarize present management and future directions in the treatment of metastatic RCC. CA Cancer J Clin 2017;67:507-524. (c) 2017 American Cancer Society.

引用

页码：507 / 524

页数：18

共 167 条

[1]

ADLER A, 1987, J BIOL RESP MODIF, V6, P610

[2] Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes [J].

Alfaro, C. ;

Suarez, N. ;

Gonzalez, A. ;

Solano, S. ;

Erro, L. ;

Dubrot, J. ;

Palazon, A. ;

Hervas-Stubbs, S. ;

Gurpide, A. ;

Lopez-Picazo, J. M. ;

Grande-Pulido, E. ;

Melero, I. ;

Perez-Gracia, J. L. .

BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1111-1119

[3] Survival After Complete Surgical Resection of Multiple Metastases From Renal Cell Carcinoma [J].

Alt, Angela L. ;

Boorjian, Stephen A. ;

Lohse, Christine M. ;

Costello, Brian A. ;

Leibovich, Bradley C. ;

Blute, Michael L. .

CANCER, 2011, 117 (13) :2873-2882

[4] Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results [J].

Amin, Asim ;

Dudek, Arkadiusz Z. ;

Logan, Theodore F. ;

Lance, Raymond S. ;

Holzbeierlein, Jeffrey M. ;

Knox, Jennifer J. ;

Master, Viraj A. ;

Pal, Sumanta K. ;

Miller, Wilson H., Jr. ;

Karsh, Lawrence I. ;

Tcherepanova, Irina Y. ;

DeBenedette, Mark A. ;

Williams, W. Lee ;

Plessinger, Douglas C. ;

Nicolette, Charles A. ;

Figlin, Robert A. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

[5] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging [J].

Amin, Mahul B. ;

Greene, Frederick L. ;

Edge, Stephen B. ;

Compton, Carolyn C. ;

Gershenwald, Jeffrey E. ;

Brookland, Robert K. ;

Meyer, Laura ;

Gress, Donna M. ;

Byrd, David R. ;

Winchester, David P. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) :93-99

[6]

[Anonymous], NIV COMB IP VERS SUN

[7]

[Anonymous], J CLIN ONCOL 1

[8]

[Anonymous], STUD AV AX VERS SUN

[9]

[Anonymous], J CLIN ONCOL S

[10]

[Anonymous], EV TREAT KIDN CANC W

← 1 2 3 4 5 6 7 8 9 10 →